NCT05999357View on ClinicalTrials.gov

JDQ443 for KRAS G12C NSCLC Brain Metastases

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

April 15, 2024

Primary Completion Date

August 31, 2027

Study Completion Date

August 31, 2028

Conditions
Non Small Cell Lung Cancer MetastaticBrain Metastases, AdultKRAS G12C
Interventions
DRUG

JDQ443

JDQ443 tablets, orally administered

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

Maastricht University Medical Center

OTHER

NCT05999357 - JDQ443 for KRAS G12C NSCLC Brain Metastases | Biotech Hunter | Biotech Hunter